Speakers:
- Melis Anahtar, Clinical Investigator, Massachusetts General Hospital (USA)
- Nicole Scarangella-Oman, Scientific Director, GSK (USA)
- Nazgul Sakenova, Postdoctoral Researcher, Harvard Medical School (USA)
- David Paterson, Director, ADVANCE-ID (Singapore)
In this webinar, individuals who have co-authored publications that have had a particular impact in antimicrobial R&D will briefly present their findings and answer questions from the audience. The following articles will be presented:
A generative deep learning approach to de novo antibiotic design (Cell, 2025)
To be presented by Melis Anahtar
Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3) (Antimicrobial Agents and Chemotherapy, 2025)
To be presented by Nicole Scarangella-Oman
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial (The Lancet Infectious Diseases, 2026)
To be presented by David Paterson
Systematic mapping of antibiotic cross-resistance and collateral sensitivity with chemical genetics (Nature Microbiology, 2025)
To be presented by Nazgul Sakenova
This live webinar including an interactive Q&A session will be broadcast on 26 March 2026. You can find your timezone here.
If you have questions or comments, please let us know: revive@gardp.org.